HHS TAGGS · Dec 2024
Synvivia received a $1,640,169 award for a Direct-to-Phase II SBIR project focused on synthetic helper genes and cyclic peptides to improve AAV vector yield and quality for gene therapy manufacturing.
Synvivia applies chemical control over cell behavior
Company research
Public company, workplace, funding, and market signals
Overview
Synvivia is a Berkeley-area synthetic biology biotech that engineers molecules to reprogram cells and uses small-molecule-controlled protein/cyclic-peptide systems to optimize gene-therapy manufacturing, especially AAV yield, potency, and infectiousness.
Primary product
AAV gene-therapy manufacturing optimization platform built around synthetic helper genes, engineered cyclic peptides, and small-molecule-controlled protein switches.
Founded
2015
Headquarters
Berkeley, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Synthetic biology / gene therapy manufacturing tools
Offices
Berkeley, California, United States
5855 Beaudry St, Emeryville, CA 94608, United States
Emeryville, California, United States
2865 7th St, Berkeley, CA 94710, United States
Business model
B2B biotechnology platform
grant-funded R&D
technology licensing and partnerships
Funding
Stage
early-stage, grant-supported biotech
Total raised
$2M
Latest round
Grant · Dec 2024
Latest amount
$1.6M
People & investors
Work & culture
Very small research-heavy company; public profile signals are strong on work-life, compensation, culture, and career, but there is no detailed public culture or benefits page.
Compensation
Public compensation data is sparse. A third-party profile surfaces a Research Associate benchmark around $88,513/year, and public employer ratings on the company profile show compensation at 5.0/5.0. No public salary bands or equity policy were found.
Product & market
Differentiators
- —Small-molecule-controlled cell behavior instead of conventional static expression systems
- —Engineered cyclic peptide discovery for AAV manufacturing gains
- —Genetically encoded biocontainment and cell-control IP rooted in UC Berkeley research
- —Reported 3-10x improvements in yield/potency for gene-therapy manufacturing
Technology
synthetic biology
protein engineering
small-molecule-controlled protein switches
cyclic peptides
AAV vector manufacturing optimization
gene therapy manufacturing
genetically encoded biocontainment
cell-behavior reprogramming
biomanufacturing platform
Customers
biopharmaceutical manufacturers
gene therapy manufacturers
AAV vector manufacturers
Competitors
Nortis
Microvascular Tissues
Helion Biotech
Invivogen
4M Therapeutics Inc.
Synthego
Avidity Biosciences
Principia Biopharma
Prometrika
Scale & contact
Estimated revenue
USD 1M-$5M
Latest news
Google Patents · Dec 2023
Patent publication describes methods for selecting and using engineered cyclic peptides to improve viral vector packaging, titer, transduction efficiency, and manufacturability.
Cognition IP · Sep 2023
Case study recounts Synvivia’s founder story, the commercialization of its biocontainment/protein-switch technology, and the role of patent protection in fundraising and IP development.
UC Berkeley IPIRA
UC Berkeley describes Synvivia as a synthetic biology company founded from Berkeley research and notes its origins in NSF/DARPA-funded work, Y Combinator participation, and exclusive IP licensing.
Jobs and careers at Synvivia
0 jobs at Synvivia
No open positions
Check back later for new openings